Ziconotide (Prialt) dosing & administration
FDA-approved intrathecal analgesic derived from cone snail venom for severe chronic pain
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Intrathecal: Infused into the fluid around the spinal cord, done in a hospital by a specialist.
Bioavailability Acts directly on the spinal cord/brain fluid — bypasses the bloodstream entirely.
Titration schedule
2.4 mcg/day
Frequency
Continuous infusion
Duration
Starting point
Ziconotide is pumped directly into the fluid around the spinal cord, using an implanted or external microinfusion device — it is NOT for intravenous administration [6]. The label starts at no more than 2.4 mcg per day (0.1 mcg per hour) [6]. Starting low matters here more than usual: the boxed warning is for severe psychiatric symptoms and neurological impairment, and the drug is contraindicated in anyone with a history of psychosis [6].
Increase up to 2.4 mcg/day per step
Frequency
No more than 2-3 times per week
Duration
Until pain is controlled
The dose is raised by up to 2.4 mcg per day at a time, no more often than 2 to 3 times a week [6]. This is one of the few genuine titrations in this library: the same patient climbs the ladder, rather than different patients being assigned different rungs. What you are titrating against is not just pain — the label directs frequent monitoring for cognitive impairment, hallucinations and changes in mood or consciousness, and discontinuation if serious neurological or psychiatric signs appear [6].
Up to 19.2 mcg/day
Frequency
Continuous infusion
Duration
Ongoing/maintenance
The recommended maximum is 19.2 mcg per day (0.8 mcg per hour), reached by about day 21 on the label's schedule [6]. Many people settle below it. Reported psychiatric events at clinical doses include hallucinations in 12%, paranoid reactions in 3%, hostility in 2%, delirium in 2%, psychosis in 1% and manic reactions in 0.4% — and the placebo-controlled trials found a higher incidence of suicide, suicide attempts and suicidal ideation on ziconotide than on placebo [6]. Slower is better tolerated than faster, and the ceiling is a ceiling, not a target.
Timing
Best time to take
Use Ziconotide (Prialt) at the same time each day for optimal results. Consistency in timing helps maintain stable levels and maximize therapeutic benefits. Follow your healthcare provider's specific instructions.
With food?
Ziconotide (Prialt) can generally be used with or without food. If you experience any discomfort, try taking it with a light meal. Follow specific guidance from your healthcare provider.
If stacking
Ziconotide (Prialt) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
- You've tolerated the current dose for the recommended period without significant side effects
- Therapeutic goals haven't been met at the current dose level
- Your healthcare provider recommends dose escalation based on your response
- Lab work or clinical assessments support a higher dose
Decrease if
- Side effects are bothersome or impacting daily life despite management strategies
- You experience any signs of an adverse reaction
- Lab results indicate the need for dose reduction
- Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- Therapeutic goals being met with minimal side effects
- Stable and consistent response to treatment
- Lab values or clinical markers trending in the right direction
- Good tolerance with manageable or absent side effects
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Storage
Before reconstitution
Store Ziconotide (Prialt) in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After reconstitution
Once reconstituted, Ziconotide (Prialt) should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: Intrathecal infusion—rotate sites if applicable
Maintain a consistent schedule for optimal results with Ziconotide (Prialt). Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Is it safe?
Side effects
Commonly reported: Dizziness, Nausea
Less common: Confusion and Memory Impairment, Ataxia and Nystagmus
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Ziconotide (Prialt)
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Ziconotide (Prialt) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
- CNS Depressants — May potentiate central nervous system depression including somnolence and confusion
- Intrathecal Opioids — Concurrent intrathecal opioids increase risk of serious adverse events including respiratory depression
- Psychotropic Medications — May exacerbate psychiatric adverse effects including hallucinations and psychosis risk
Published research
What the studies show
Picañol J, et al. · 2025
Meta-analysis of ziconotide showed significant pain reduction (22.54-point improvement) versus placebo with 17.85% serious adverse events. Secondary outcomes suggest potential opioid sparing, though evidence quality was moderate.
Canovas Martínez L, et al. · 2025
Five patients successfully reduced morphine doses by 50% after 6 weeks of ziconotide titration while achieving pain reduction from 8.0 to 2.5. Neuropathic symptoms improved dramatically with 80% reduction in tingling.
Wahezi S, et al. · 2026
A narrative review established ziconotide as a selective Cav2.2 channel blocker offering precise pain relief through intrathecal delivery for refractory chronic pain. Combined with morphine, it reduced opioid requirements.
Gan H, et al. · 2025
No abstract available for comprehensive analysis.
Noe G, et al. · 2025
No abstract available for comprehensive analysis.
TerSera / U.S. FDA · 2023
PRIALT is delivered only by intrathecal infusion. Start at no more than 2.4 mcg/day (0.1 mcg/hr) and titrate in increments of up to 2.4 mcg/day no more than 2 to 3 times per week, based on response and side effects, to a maximum of 19.2 mcg/day (0.8 mcg/hr).
Head to head
Ziconotide (Prialt) compared
Studied for
Conditions Ziconotide (Prialt) has been researched in
Want the full picture?
The complete Ziconotide (Prialt) research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.